The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of Adverse Events
Timeframe: From time of enrollment for up to 10 years
Selected Events of Interest in Patients with Hereditary Transthyretin-mediated (hATTR) Amyloidosis (ATTRv Amyloidosis)
Timeframe: From 1 year prior to enrollment for up to 10 years
Health Care Provider (HCP)-Assessed Polyneuropathy (PND) Disability Score
Timeframe: Up to 11 years
HCP-Assessed Familial Amyloidotic Polyneuropathy (FAP) Score
Timeframe: Up to 11 years
HCP-Assessed Neuropathy Impairment Score (NIS)
Timeframe: Up to 11 years
HCP-Assessed Cardiomyopathy
Timeframe: Up to 11 years
HCP- Assessed Cardiopulmonary Exercise Testing (CPET) Performance
Timeframe: Up to 11 years
Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score
Timeframe: Up to 11 years
Alnylam Clinical Trial Information Line
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Timeframe: Up to 11 years
Rasch-built Overall Disability Scale (R-ODS)
Timeframe: Up to 11 years